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Abstract: Epidermolytic ichthyosis (EI) is a rare disorder of
cornification caused by mutations in KRT1 and KRT10, encoding
two suprabasal epidermal keratins. Because of the variable clinical
features and severity of the disease, histopathology is often
required to correctly direct the molecular analysis. EI is character-
ized by hyperkeratosis and vacuolar degeneration of the upper
epidermis, also known as epidermolytic hyperkeratosis, hence the
name of the disease. In the current report, the authors describe
members of 2 families presenting with clinical features consistent
with EI. The patients were shown to carry classical mutations in
KRT1 or KRT10, but did not display epidermolytic changes on
histology. These observations underscore the need to remain aware
of the limitations of pathological features when considering a diag-
nosis of EI.
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INTRODUCTION
Epidermolytic ichthyosis (EI; MIM 113800), formerly
known as epidermolytic hyperkeratosis or bullous congenital
ichthyosiform erythroderma, is a rare and clinically hetero-
geneous disorder of cornification.1 EI is usually inherited in
a dominant fashion, but rarely is recessive (MIM 113800) or
semidominant, and is caused by mutations in KRT1 and
KRT10, which encode the 2 major suprabasal keratins, keratin
1 and keratin 10, respectively.2–4 EI is characterized by blis-
tering in early life followed by generalized ichthyosis of vary-
ing severity, sometimes associated with diffuse palmoplantar
keratoderma.1 Rarer variants of EI include annular (MIM
607602) and nevoid (MIM 162900) forms of the disease. In
addition, mutations in KRT1 and KRT10 have been associated
with a variety of non-EI phenotypes such as ichthyosis with
confetti (MIM 609165)5 and ichthyosis hystrix of Curth-
Macklin (MIM 146590).6
Epidermolytic hyperkeratosis, the histopathological
hallmark of EI, is characterized by vacuolar degeneration of
suprabasal keratinocytes and coarse keratohyalin granules in
the thickened granular layer, often associated with intra-
cytoplasmic and perinuclear eosinophilic inclusions, which
reflect tonofilaments clumping on electron microscopy.7
Because of the variable clinical manifestations of
mutations in KRT1 and KRT101 and the fact that EI shares
many clinical features with other disorders of cornification,8
histopathology is often used to direct molecular analyses in
cases of suspected EI.7 Here, we present 2 cases clinically
consistent with EI and caused by classical mutations in KRT1




The patients and their healthy family members provided
written and informed consent to participate in this study
according to a protocol approved by the institutional review
board at each site and by the Israel National Committee for
Human Genetic Studies in adherence with the Helsinki
principles. Skin biopsies were obtained from clinically
affected areas for histological examination and immunostain-
ing. DNA was extracted from peripheral blood leukocytes
using the 5 Prime ArchivePure DNA Blood Kit (5 Prime Inc,
Gaithersburg, MD).
Immunohistochemical Studies
Four mm paraffin-embedded sections were kept over-
night at 608C and deparaffinized. After permeabilization and
antigen retrieval sections were blocked in 1% bovine serum
albumin, 2% normal goat serum and incubated with primary
antibodies, as previously described.9 Primary antibodies used
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were mouse monoclonal 4B2 (anti-desmoglein 110; 1:100 dilu-
tion), mouse monoclonal 11-5F (anti-desmoplakin, gift from
Dr. David Garrod, 1:100 dilution), and chicken polyclonal
1407 (anti-plakoglobin,11 diluted 1:1000). Secondary antibody
staining was performed for 30 minutes at 378C using Alexa Fluor
anti-mouse, anti-rabbit, or anti-chicken secondary antibodies
(1:300 dilution; Life Technologies/Invitrogen, Carlsbad, CA).
Exome Sequencing
Exome sequencing of individuals I-1, II-1, III-2, III-3,
and IV-1 from family 1 (case 1) was performed by
Otogenetics corporation using in-solution hybridization with
Agilent AV5 + UTR Exome (71 Mb) version 4.0 (Agilent,
Santa Clara) followed by massively parallel sequencing (Illu-
mina HiSeq2000) with 100-bp paired-end reads. In the case of
family 2, exome sequencing was performed by BGI Tech
Solutions Ltd using in-solution hybridization with SureSelect
All Exon 51 Mb Version 4.0 followed by massively parallel
sequencing (Illumina HiSeq2000) with 100-bp paired-end
reads. Reads were aligned to the Genome Reference Consor-
tium Human Build 37 (GRCh37/hg19) using Burrows-
Wheeler Aligner (BWA).12 Exome sequencing data analysis
was performed as previously described.9
Sanger Sequencing
Genomic DNA was polymerase chain reaction ampli-
fied using the oligonucleotide primer pair: 50-TCAACTGAA-
CAAGG-30 and 50-TACTCTACCCTCTCT-30, spanning
KRT10 exon 6. Coding sequences and flanking intronic
boundaries of KRT1 were polymerase chain reaction ampli-
fied as previously described.13 Gel-purified (QIAquick
gel extraction kit; QIAGEN, Hilden, Germany) amplicons
were subjected to bidirectional DNA sequencing with the




A four-generation kindred of Russian descent (Fig. 1A)
presented with localized symmetric well-defined hyperkera-
totic plaques which first developed at 5–6 years of age. The
lesions were most prominent on the elbows, knees, hips, and
dorsal feet, but in some cases also involved flexural areas
such as axillae and groin. Some of the lesions clinically
resembled plaque-type psoriasis. There was no history of
blistering or skin fragility (Fig. 1B).
Histologically, psoriasiform hyperplasia with mild
papillomatosis, minimal spongiosis, hypogranulosis, para-
keratosis, and superficial perivascular lymphocytic infiltrate
were observed. Small foci of intercellular separation in the
spinous layer without gross epidermolytic changes or overt
acantholysis were present (Fig. 1C).
Deep sequencing followed by validation through direct
sequencing revealed that all affected members of family 1
harbor a heterozygous G.C transversion at position 1322 of
the KRT10 gene cDNA (Fig. 1D). The mutation is predicted
to result in the substitution of a proline residue for a conserved
arginine amino acid at position 441 of the amino acid
sequence of the KRT10 protein (p.R441P). The mutation,
which has been previously reported in a case of EI,14 was
FIGURE 1. Clinical and molecular
features of family 1. A, Family pedi-
gree. Black symbols denote affected
individuals; (B) clinical features
include well-demarcated hyperkera-
totic plaques in the axillae, knees,
ankles, and feet; (C) histological fea-
tures comprise psoriasiform hyperpla-
sia with mild papillomatosis, minimal
spongiosis, hypogranulosis, para-
keratosis, and superficial perivascular
lymphocytic infiltrate. Small foci of
intercellular separation in the spinous
layer are present (hematoxylin and
eosin, X200); (D) direct sequencing
revealed a heterozygous c.1322 G.C
(p.R441P) mutation in KRT10 in the
affected family members (lower
panel). The wild-type (WT) sequence
is given for comparison. The position
of the mutation is underlined.
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absent in the nonaffected members of the family and was
absent from all available public databases (ESP, UCSC,
NCBI, HGMD, Ensembl, 1000 genomes).
Family 2
A 2-year-old boy, the only child of unrelated healthy
parents of mixed Northern European descent, was born with
generalized hypotrichosis, erythroderma, and skin peeling
(Fig. 2A). Histopathological analysis of a skin biopsy at 2 days
of age revealed cell–cell dissociation throughout the entire
epidermis with foci of acantholysis (Fig. 2B). During the first
9 months of life, he also had failure to thrive and recurrent
Staphylococcus aureus infections of the skin and blood, neces-
sitating recurrent hospitalizations. Immunostaining for LEKTI,
performed because of suspected Netherton syndrome, was nor-
mal (data not shown). Given the acantholysis, erythroderma,
and hypotrichosis suggestive of a desmosomal defect,15 we
scrutinized all coding sequences and intronic boundaries of
a number of genes encoding desmosomal proteins, including
DSG1, DSP, JUP, PKP1, and CDSN, previously associated
with similar clinical and/or pathological features,15 as well as
DSC1. No pathogenic mutations were identified.
Whole-exome sequencing then revealed a novel
c.562A.C missense mutation in KRT1, predicted to result
in the substitution of asparagine for histidine at position
188 of the protein sequence (p.N188H) (Fig. 2C). The muta-
tion was absent in both parents, suggesting that it appeared de
novo in the affected child or resulted from gonadal mosai-
cism. Supporting the pathogenicity of this mutation, it was
found to affect a highly conserved residue (Conseq = 9,
range = 1–9; http://conseq.tau.ac.il/) and is predicted to be
pathogenic by both SIFT (0, range 1–0)16 and POLYPHEN
(1, range 0–1)17 software, used to estimate the possible impact
of an amino acid substitution on the protein function. Finally,
a number of other mutations have been reported to affect the
same residue.18–22
A systematic inspection of the deep sequencing data
failed to reveal another pathogenic mutation to explain the
acantholytic changes seen on histology, with the possible
exception of a heterozygous missense mutation found in the
patient and his father in the A2ML1 gene, encoding a major
autoantigen in paraneoplastic pemphigus.23 The A2ML1
sequence change, c.3145C.G, is predicted to lead to the
substitution of a poorly conserved glutamine for glutamic acid
(p.Q1049E), casting doubt as to its significance (not shown).
In an attempt to provide an explanation for the loss of cell–
cell adhesion in the epidermis in the patient, we stained the
patient biopsy for a number of adhesion molecules. We
observed dramatically diminished expression of desmoglein
1, desmoplakin, and plakoglobin (Fig. 3). Throughout the first
year of life, the patient had progressively fewer cutaneous
S. aureus infections, but his skin grew increasingly more
keratotic with extensive palmoplantar thickening. He contin-
ued to show blistering, prompting performance of a second
biopsy at 2 years of age. Biopsy sections now revealed typical
epidermolytic changes and hyperkeratosis (Fig. 2D).
DISCUSSION
The clinical spectrum of EI is broad, ranging from
severe generalized disease, characterized by blistering in early
FIGURE 2. Clinical and molecular
features in family 2. A, Clinical fea-
tures included erythroderma associ-
ated with diffuse skin peeling; (B)
a skin biopsy obtained at 2 days of
age showed cell–cell disadhesion
and foci of acantholysis (arrows)
(hematoxylin and eosin, X40); (C)
Sanger sequencing revealed a het-
erozygous c.562A.C (p.N188H)
mutation in KRT1 in the affected
child (upper panel) which was
absent in his father (middle panel)
and mother (lower panel). The
position of the mutation is under-
lined; (D) a skin biopsy obtained at
age 2 years showed epidermolytic
changes in the upper epidermal lay-
ers (hematoxylin and eosin, ·40).
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life and widespread ichthyosis in adult life to mild phenotypes
such as isolated palmoplantar keratoderma.1 The disease is
caused by mutations affecting conserved regions primarily
located at the beginning and end of the central alpha-helical
rod of keratin molecules.4 Absence of epidermolytic changes
is typical of disorders of cornification resulting from muta-
tions affecting KRT1 or KRT10 domains located outside those
regions.6,24 In contrast, here, we report absence of epidermo-
lytic changes despite the presence of mutations affecting
highly conserved regions of the rod domain.
The mutation detected in family 1 has been previously
reported in a mild case of EI.25 Interestingly, the phenotypes
reported in our patient and in this previous report were
remarkably similar both at the clinical and histopathological
levels.25 Although it is highly conserved, it is possible that the
residue affected by this recurrent mutation does not mediate
keratin dimer formation but rather is involved in late
differentiation-related events.25
In contrast with this first case, the patient of family 2
displayed a very severe phenotype featuring erythroderma,
blistering, and peeling of the entire surface of the skin.
Histology was remarkable for evidence of compromised cell–
cell adhesion, which correlated with decreased expression of
several major desmosomal proteins, suggesting that the
p.N188H mutation in KRT1 may alter keratinocyte cell–cell
adhesion. Because other mutations have been shown to affect
the p.N188 residue (p.N188S, p.N188T, and p.N188K)18–22
and to be associated with epidermolysis, it is tempting to
suggest that the effect of the p.R188H mutation is specifically
due to the nature of the substitution.
The pathomechanism underlying the effect of the
p.N188H mutation on cell–cell adhesion remains to be inves-
tigated. Desmoplakin connects the intermediate filament net-
work to the desmosomal plaque.26 In the absence of functional
keratins, desmosomal adhesion is compromised.27 Desmopla-
kin has been shown to interact with the keratin 1 head
domain.28,29 As p.N188H affects a residue located within the
1A domain of the keratin 1 protein, it is unclear whether the
mutation leads to desmosomal destabilization through a direct
effect on desmoplakin-keratin 1 interaction, as shown for other
keratins,30 or exert a deleterious effect on desmosomal stability
indirectly by interfering with keratin dimerization, which has
also been shown to be critical for desmoplakin interaction with
intermediate filaments in some experimental systems.30,31 Of
note, although no epidermolytic changes were visible in the
biopsy obtained perinatally in the family 2 patient, a biopsy
obtained in early infancy revealed vacuolar degeneration of the
upper epidermal layers. The coexistence in the same individual
of epidermolytic changes and acantholysis has been reported in
the past in EI but is likely to be rare.32 Of note, cell–cell
separation (but not overt acantholysis) was noticed in case 1.
In summary, the present report and a previous study14
call for caution when interpreting the lack of epidermolytic
changes in a case clinically suggestive of EI.
REFERENCES
1. DiGiovanna JJ, Bale SJ. Clinical heterogeneity in epidermolytic hyper-
keratosis. Arch Dermatol. 1994;130:1026–1035.
2. Nousbeck J, Padalon-Brauch G, Fuchs-Telem D, et al. Semidominant
inheritance in epidermolytic ichthyosis. J Invest Dermatol. 2013;133:
2626–2628.
3. Muller FB, Huber M, Kinaciyan T, et al. A human keratin 10 knockout
causes recessive epidermolytic hyperkeratosis. Hum Mol Genet. 2006;15:
1133–1141.
4. Lane EB, McLean WH. Keratins and skin disorders. J Pathol. 2004;204:
355–366.
5. Choate KA, Lu Y, Zhou J, et al. Mitotic recombination in patients with
ichthyosis causes reversion of dominant mutations in KRT10. Science.
2010;330:94–97.
6. Sprecher E, Ishida-Yamamoto A, Becker OM, et al. Evidence for novel
functions of the keratin tail emerging from a mutation causing ichthyosis
hystrix. J Invest Dermatol. 2001;116:511–519.
7. Bergman R, Khamaysi Z, Sprecher E. A unique pattern of dyskeratosis
characterizes epidermolytic hyperkeratosis and epidermolytic palmoplan-
tar keratoderma. Am J Dermatopathol. 2008;30:101–105.
8. Oji V, Tadini G, Akiyama M, et al. Revised nomenclature and classifi-
cation of inherited ichthyoses: results of the first ichthyosis Consensus
Conference in Soreze 2009. J Am Acad Dermatol. 2010;63:607–641.
9. Samuelov L, Sarig O, Harmon RM, et al. Desmoglein 1 deficiency results
in severe dermatitis, multiple allergies and metabolic wasting. Nat Genet.
2013;45:1244–1248.
10. Dusek RL, Getsios S, Chen F, et al. The differentiation-dependent des-
mosomal cadherin desmoglein 1 is a novel caspase-3 target that regulates
apoptosis in keratinocytes. J Biol Chem. 2006;281:3614–3624.
FIGURE 3. Immunostaining for desmosomal proteins. Skin
sections from the biopsy obtained from the patient at 2 days of
age and from a control subject were immunostained for des-
mosomal components desmoglein 1 (DSG1), desmoplakin
(DSP), and plakoglobin (PG). Top panels, staining for des-
moglein 1 (DSG1, red) captured at 10· magnification,
calibration bar 100 mm. Nuclei were visualized with
4060-diamidino-2-phenylindole (DAPI). Middle and lower
panels, staining for desmoplakin (DSP) and PG, respectively,
captured at 40· magnification, calibration bar 20 mm. Des-
moglein 1 and desmoplakin are drastically reduced in the
patient epidermis, and PG staining is also weaker in the patient
skin compared with the control biopsy.
Am J Dermatopathol  Volume 39, Number 6, June 2017 Epidermolytic Ichthyosis Sine Epidermolysis
Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved. www.amjdermatopathology.com | 443
Copyright  2017 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
11. Gaudry CA, Palka HL, Dusek RL, et al. Tyrosine-phosphorylated plako-
globin is associated with desmogleins but not desmoplakin after epidermal
growth factor receptor activation. J Biol Chem. 2001;276:24871–24880.
12. Li H, Durbin R. Fast and accurate long-read alignment with Burrows-
Wheeler transform. Bioinformatics. 2010;26:589–595.
13. Whittock NV, Eady RA, McGrath JA. Genomic organization and ampli-
fication of the human epidermal type II keratin genes K1 and K5. Bio-
chem Biophys Res Commun. 2000;274:149–152.
14. Mirza H, Kumar A, Craiglow BG, et al. Mutations affecting keratin 10
surface-Exposed residues Highlight the Structural Basis of phenotypic Var-
iation in epidermolytic ichthyosis. J Invest Dermatol. 2015;135:3041–3050.
15. Samuelov L, Sprecher E. Inherited desmosomal disorders. Cell Tissue
Res. 2015;360:457–475.
16. Kumar P, Henikoff S, Ng PC. Predicting the effects of coding non-
synonymous variants on protein function using the SIFT algorithm.
Nat Protoc. 2009;4:1073–1081.
17. Adzhubei IA, Schmidt S, Peshkin L, et al. A method and server for
predicting damaging missense mutations. Nat Methods. 2010;7:248–249.
18. McLean WH, Eady RA, Dopping-Hepenstal PJ, et al. Mutations in the
rod 1A domain of keratins 1 and 10 in bullous congenital ichthyosiform
erythroderma (BCIE). J Invest Dermatol. 1994;102:24–30.
19. Arin MJ, Longley MA, Kuster W, et al. An asparagine to threonine
substitution in the 1A domain of keratin 1: a novel mutation that causes
epidermolytic hyperkeratosis. Exp Dermatol. 1999;8:124–127.
20. Nomura K, Umeki K, Hatayama I, et al. Phenotypic heterogeneity in
bullous congenital ichthyosiform erythroderma: possible somatic mosa-
icism for keratin gene mutation in the mildly affected mother of the
proband. Arch Dermatol. 2001;137:1192–1195.
21. Arin MJ, Oji V, Emmert S, et al. Expanding the keratin mutation database:
novel and recurrent mutations and genotype-phenotype correlations in 28
patients with epidermolytic ichthyosis. Br J Dermatol. 2011;164:442–447.
22. Lee DY, Ahn KS, Lee CH, et al. Two novel mutations in the keratin 1 gene
in epidermolytic hyperkeratosis. J Invest Dermatol. 2002;119:976–977.
23. Schepens I, Jaunin F, Begre N, et al. The protease inhibitor alpha-2-
macroglobulin-like-1 is the p170 antigen recognized by paraneoplastic
pemphigus autoantibodies in human. PLoS One. 2010;5:e12250.
24. Kimonis V, DiGiovanna JJ, Yang JM, et al. A mutation in the V1 end
domain of keratin 1 in non-epidermolytic palmar-plantar keratoderma.
J Invest Dermatol. 1994;103:764–769.
25. Mirza H, Kumar A, Craiglow BG, et al. Mutations affecting keratin 10
surface-exposed residues highlight the structural basis of phenotypic vari-
ation in epidermolytic ichthyosis. J Invest Dermatol. 2015;135:3041–3050.
26. Simpson CL, Patel DM, Green KJ. Deconstructing the skin: cytoarchi-
tectural determinants of epidermal morphogenesis. Nat Rev Mol Cell
Biol. 2011;12:565–580.
27. Bar J, Kumar V, Roth W, et al. Skin fragility and impaired desmosomal
adhesion in mice lacking all keratins. J Invest Dermatol. 2014;134:
1012–1022.
28. Meng JJ, Bornslaeger EA, Green KJ, et al. Two-hybrid analysis reveals
fundamental differences in direct interactions between desmoplakin and
cell type-specific intermediate filaments. J Biol Chem. 1997;272:21495–
21503.
29. Kouklis PD, Hutton E, Fuchs E. Making a connection: direct binding
between keratin intermediate filaments and desmosomal proteins. J Cell
Biol. 1994;127:1049–1060.
30. Fontao L, Favre B, Riou S, et al. Interaction of the bullous pemphigoid
antigen 1 (BP230) and desmoplakin with intermediate filaments is medi-
ated by distinct sequences within their COOH terminus. Mol Biol Cell.
2003;14:1978–1992.
31. Kroger C, Loschke F, Schwarz N, et al. Keratins control intercellular
adhesion involving PKC-alpha-mediated desmoplakin phosphorylation.
J Cell Biol. 2013;201:681–692.
32. Ross R, DiGiovanna JJ, Capaldi L, et al. Histopathologic characterization
of epidermolytic hyperkeratosis: a systematic review of histology from
the national registry for ichthyosis and related skin disorders. J Am Acad
Dermatol. 2008;59:86–90.
Eskin-Schwartz et al Am J Dermatopathol  Volume 39, Number 6, June 2017
444 | www.amjdermatopathology.com Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.
Copyright  2017 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
